Description
Vaborbactam is a selective beta-lactamase inhibitor under the development of Rempex Pharmaceuticals. Vaborbactam is a broad-spectrum inhibitor, especially restoring the activity of carbapenems against KPC-producing strains. Combined with a carbapenem, Vaborbactam can be a promising product for the treatment of multidrug resistant Gram-negative bacteria. Phase III clinical trials for the treatment of Bacteraemia, Gram-negative infections, Pneumonia, Pyelonephritis and Urinary tract infections are on-going